Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The cytotoxic drug mitozolomide has been found to cause unpredictably severe thrombocytopenia during phase I and II clinical trials. In an attempt to relate dose and pharmacokinetic parameters to toxicity, we measured plasma concentrations of mitozolomide in 14 patients with a range of malignancies. There were significant correlations (Spearman rank correlation test) between drug clearance and AUC and white blood cell nadir. The pharmacokinetic and toxicity data were not normally distributed; therefore, it was not possible to construct predictive nomograms for toxicity based on linear regression analysis.

Original publication

DOI

10.1007/bf00686236

Type

Journal article

Journal

Cancer Chemother Pharmacol

Publication Date

1990

Volume

25

Pages

352 - 354

Keywords

Adult, Aged, Antineoplastic Agents, Female, Humans, Leukocyte Count, Male, Middle Aged, Nitrogen Mustard Compounds, Platelet Count